MNPR vs. ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, PRAX, and NRIX
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.
Monopar Therapeutics vs.
Ardelyx (NASDAQ:ARDX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Monopar Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ardelyx currently has a consensus price target of $10.39, indicating a potential upside of 160.37%. Monopar Therapeutics has a consensus price target of $55.33, indicating a potential upside of 55.61%. Given Ardelyx's stronger consensus rating and higher possible upside, equities analysts plainly believe Ardelyx is more favorable than Monopar Therapeutics.
In the previous week, Ardelyx had 7 more articles in the media than Monopar Therapeutics. MarketBeat recorded 12 mentions for Ardelyx and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.93 beat Ardelyx's score of 0.85 indicating that Monopar Therapeutics is being referred to more favorably in the news media.
Ardelyx has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Ardelyx received 493 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 73.02% of users gave Monopar Therapeutics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.
Monopar Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Monopar Therapeutics' return on equity.
Summary
Ardelyx beats Monopar Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MNPR) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy MNPR Stock Free MNPR Stock Alerts